FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2171438857> ?p ?o ?g. }

• W2171438857 endingPage "1227" @default.
• W2171438857 startingPage "1215" @default.
• W2171438857 abstract "Integrin alpha(v)beta(3) and vascular endothelial growth factor receptor 2 (Flk-1) have been shown to be involved in tumor-induced angiogenesis. Selective targeting of upregulated alpha(v)beta(3) and Flk-1 on the neovasculature of tumors is a novel antiangiogenesis strategy for treating a wide variety of solid tumors. In the studies described here, we investigated the potential therapeutic efficacy of two three-component treatment regimens using two murine tumor models.The treatment regimens used nanoparticle (NP) based targeting agents radiolabeled with (90)Y. The small molecule integrin antagonist (IA) 4-[2-(3,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]-benzoyl-2-(5)-aminoethylsulfonylamino-beta-alanine, which binds to the integrin alpha(v)beta(3), and a monoclonal antibody against murine Flk-1 (anti-Flk-1 MAb) were used to target the NPs. Murine tumor models K1735-M2 (melanoma) and CT-26 (colon adenocarcinoma) were used to evaluate the treatment efficacy.In K1735-M2 and CT-26 tumors, a single treatment with IA-NP-(90)Y (14.2 microg/g IA, 5 or 6 microCi/g (90)Y) caused a significant tumor growth delay compared to untreated control tumors, as well as tumors treated with IA, IA-NP, and NP-(90)Y, respectively (p < 0.025, Wilcoxon test). In K1735-M2 tumors, a single treatment with anti-Flk-1 MAb-NP-(90)Y (0.36 microg/g anti-Flk-1 MAb, 5 microCi/g (90)Y) also caused a significant tumor growth delay (p < 0.05, Wilcoxon test) compared to untreated tumors, as well as tumors treated with anti-Flk-1 MAb, anti-Flk-1 MAb-NP, and conventional radioimmunotherapy with (90)Y-labeled anti-Flk mAb. Anti-CD31 staining showed a marked decrease in vessel density in tumors treated with anti-Flk-1 MAb-NP-(90)Y, which was associated with a high level of apoptotic death in these tumors, as shown by terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling staining.The present studies provide proof of principle that targeted radiotherapy works using different targeting agents on a nanoparticle, to target both the integrin alpha(v)beta(3) and the vascular endothelial growth factor receptor. These encouraging results demonstrate the potential therapeutic efficacy of the IA-NP-(90)Y and anti-Flk-1 MAb-NP-(90)Y complexes as novel therapeutic agents for the treatment of a variety of tumor types." @default.
• W2171438857 created "2016-06-24" @default.
• W2171438857 creator A5018176610 @default.
• W2171438857 creator A5022053971 @default.
• W2171438857 creator A5023896813 @default.
• W2171438857 creator A5032083671 @default.
• W2171438857 creator A5032524476 @default.
• W2171438857 creator A5039016687 @default.
• W2171438857 creator A5039097453 @default.
• W2171438857 creator A5044989774 @default.
• W2171438857 creator A5051974079 @default.
• W2171438857 creator A5064516346 @default.
• W2171438857 creator A5078481930 @default.
• W2171438857 creator A5090898520 @default.
• W2171438857 creator A5059121395 @default.
• W2171438857 date "2004-03-01" @default.
• W2171438857 modified "2023-10-15" @default.
• W2171438857 title "A novel antiangiogenesis therapy using an integrin antagonist or anti–Flk-1 antibody coated 90Y-labeled nanoparticles" @default.
• W2171438857 cites W1970405229 @default.
• W2171438857 cites W1978699285 @default.
• W2171438857 cites W1986555822 @default.
• W2171438857 cites W1990036692 @default.
• W2171438857 cites W2001054460 @default.
• W2171438857 cites W2001753204 @default.
• W2171438857 cites W2003366243 @default.
• W2171438857 cites W2012852444 @default.
• W2171438857 cites W2020307752 @default.
• W2171438857 cites W2029773366 @default.
• W2171438857 cites W2034228245 @default.
• W2171438857 cites W2035693645 @default.
• W2171438857 cites W2046507292 @default.
• W2171438857 cites W2048640269 @default.
• W2171438857 cites W2050085273 @default.
• W2171438857 cites W2057149384 @default.
• W2171438857 cites W2058418451 @default.
• W2171438857 cites W2058651524 @default.
• W2171438857 cites W2071709259 @default.
• W2171438857 cites W2074244880 @default.
• W2171438857 cites W2077391174 @default.
• W2171438857 cites W2113267611 @default.
• W2171438857 cites W2174852849 @default.
• W2171438857 cites W2324677651 @default.
• W2171438857 cites W4244550254 @default.
• W2171438857 doi "https://doi.org/10.1016/j.ijrobp.2003.10.057" @default.
• W2171438857 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15001266" @default.
• W2171438857 hasPublicationYear "2004" @default.
• W2171438857 type Work @default.
• W2171438857 sameAs 2171438857 @default.
• W2171438857 citedByCount "147" @default.
• W2171438857 countsByYear W21714388572012 @default.
• W2171438857 countsByYear W21714388572013 @default.
• W2171438857 countsByYear W21714388572014 @default.
• W2171438857 countsByYear W21714388572015 @default.
• W2171438857 countsByYear W21714388572016 @default.
• W2171438857 countsByYear W21714388572017 @default.
• W2171438857 countsByYear W21714388572018 @default.
• W2171438857 countsByYear W21714388572019 @default.
• W2171438857 countsByYear W21714388572020 @default.
• W2171438857 countsByYear W21714388572021 @default.
• W2171438857 countsByYear W21714388572022 @default.
• W2171438857 countsByYear W21714388572023 @default.
• W2171438857 crossrefType "journal-article" @default.
• W2171438857 hasAuthorship W2171438857A5018176610 @default.
• W2171438857 hasAuthorship W2171438857A5022053971 @default.
• W2171438857 hasAuthorship W2171438857A5023896813 @default.
• W2171438857 hasAuthorship W2171438857A5032083671 @default.
• W2171438857 hasAuthorship W2171438857A5032524476 @default.
• W2171438857 hasAuthorship W2171438857A5039016687 @default.
• W2171438857 hasAuthorship W2171438857A5039097453 @default.
• W2171438857 hasAuthorship W2171438857A5044989774 @default.
• W2171438857 hasAuthorship W2171438857A5051974079 @default.
• W2171438857 hasAuthorship W2171438857A5059121395 @default.
• W2171438857 hasAuthorship W2171438857A5064516346 @default.
• W2171438857 hasAuthorship W2171438857A5078481930 @default.
• W2171438857 hasAuthorship W2171438857A5090898520 @default.
• W2171438857 hasConcept C126322002 @default.
• W2171438857 hasConcept C141071460 @default.
• W2171438857 hasConcept C142724271 @default.
• W2171438857 hasConcept C150903083 @default.
• W2171438857 hasConcept C159654299 @default.
• W2171438857 hasConcept C170493617 @default.
• W2171438857 hasConcept C195687474 @default.
• W2171438857 hasConcept C203014093 @default.
• W2171438857 hasConcept C207001950 @default.
• W2171438857 hasConcept C2775944032 @default.
• W2171438857 hasConcept C2780394083 @default.
• W2171438857 hasConcept C49453240 @default.
• W2171438857 hasConcept C502942594 @default.
• W2171438857 hasConcept C542903549 @default.
• W2171438857 hasConcept C64943373 @default.
• W2171438857 hasConcept C71924100 @default.
• W2171438857 hasConcept C86803240 @default.
• W2171438857 hasConceptScore W2171438857C126322002 @default.
• W2171438857 hasConceptScore W2171438857C141071460 @default.
• W2171438857 hasConceptScore W2171438857C142724271 @default.
• W2171438857 hasConceptScore W2171438857C150903083 @default.
• W2171438857 hasConceptScore W2171438857C159654299 @default.
• W2171438857 hasConceptScore W2171438857C170493617 @default.

• next